Personalis (NASDAQ:PSNL) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Personalis (NASDAQ:PSNL) issued its quarterly earnings data on Tuesday. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04, Zacks reports. Personalis had a negative net margin of 113.70% and a negative return on equity of 47.57%. Personalis updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.

Personalis Price Performance

Personalis stock traded down $0.27 during trading hours on Tuesday, hitting $8.73. The company had a trading volume of 1,775,260 shares, compared to its average volume of 1,283,775. Personalis has a fifty-two week low of $2.83 and a fifty-two week high of $10.95. The firm’s fifty day moving average is $7.18 and its 200-day moving average is $6.01. The firm has a market capitalization of $774.18 million, a P/E ratio of -6.82 and a beta of 1.92.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Royal Bank of Canada grew its stake in Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after buying an additional 2,395 shares during the last quarter. Howland Capital Management LLC grew its stake in Personalis by 0.9% in the 2nd quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock valued at $1,872,000 after buying an additional 2,500 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Personalis in the second quarter worth $30,000. BNP Paribas Financial Markets grew its stake in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after acquiring an additional 5,177 shares during the last quarter. Finally, Focus Partners Wealth acquired a new position in Personalis during the 1st quarter valued at $47,000. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Wednesday, October 8th. Wall Street Zen raised shares of Personalis from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. BTIG Research raised their target price on shares of Personalis from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $8.50 target price on shares of Personalis in a research report on Monday, September 8th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.25.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.